Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 16/20 | 0.76 |
| ▸ | JAK3 | P52333 | 5/20 | 0.50 |
| ▸ | LCK | P06239 | 5/20 | 0.50 |
| ▸ | EGFR | P00533 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL895163 | 1.00 | BTK (0.76) | BTKJAK3LCKEGFR | |
| SCHEMBL27851830 | 0.93 | BTK (0.66) | BTKJAK3LCKEGFR | |
| SCHEMBL894662 | 0.89 | BTK (0.59) | BTKJAK3LCKEGFR | |
| SCHEMBL13052205 | 0.89 | BTK (0.59) | BTKJAK3LCKEGFR | |
| SCHEMBL16763644 | 0.86 | BTK (1.00) | BTKJAK3LCKEGFR | |
| SCHEMBL16763641 | 0.86 | BTK (1.00) | BTKJAK3LCKEGFR | |
| SCHEMBL894600 | 0.86 | BTK (0.76) | BTKJAK3LCKEGFR | |
| SCHEMBL894602 | 0.86 | BTK (0.76) | BTKJAK3LCKEGFR | |
| SCHEMBL894625 | 0.84 | BTK (0.67) | BTKJAK3LCKEGFR | |
| SCHEMBL894624 | 0.84 | BTK (0.67) | BTKJAK3LCKEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8586751-B2 | Nicotinamide compounds useful as kinase modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-11-19 | — | — | US | disclosed |
| US-20120082702-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MEYERS SQUIBB COMPANY | 2012-04-05 | — | — | US | disclosed |
| US-20120082702-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MEYERS SQUIBB COMPANY | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120082702-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | NADK, BTK, NAMPT | BTK 2/4885JAK3 418/4885LCK 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.